13F Holdings
中文EN

GSK GSK plc IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1131399 · Reporting currency GBP

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY4.1%
TTM net income YoY122.0%
TTM EPS YoY123.2%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR-27.4%

Margins

Gross margin72.4%
Operating margin24.3%
Net margin17.5%
FCF margin19.6%
EBITDA margin31.4%

Returns

ROE38.0%
ROA9.5%
ROIC (approx.)23.4%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets73.9%
Debt / equity1.08x
Current ratio0.82x
Interest coverage11.32x

Cash quality & payout

Operating cash flow / net income1.35x
Accruals ratio-3.4%
Payout ratio44.9%
Capex / revenue4.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: GBP FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue32.67B31.38B30.33B29.32B24.70B
Cost of revenue9.02B9.05B8.56B9.55B8.16B
Gross profit23.65B22.33B21.76B19.77B16.53B
R&D expense7.53B6.40B6.22B5.49B5.02B
SG&A expense9.09B11.02B9.38B8.37B7.07B
Operating income7.93B4.02B6.75B6.43B4.36B
Interest expense701.00M669.00M792.00M879.00M769.00M
Pretax income7.40B3.48B6.06B5.63B3.60B
Income tax1.11B526.00M756.00M707.00M83.00M
Net income5.72B2.58B4.93B14.96B4.38B
EBITDA10.25B6.57B9.04B8.58B6.48B
EPS (basic)1.410.631.223.711.10
EPS (diluted)1.390.621.203.661.08
Weighted avg. shares (diluted)4.12B4.14B4.11B4.08B4.05B
Balance sheet
Cash & equivalents3.40B3.87B2.94B3.72B4.27B
Receivables7.47B6.84B7.38B7.05B7.86B
Inventory5.92B5.67B5.50B5.15B5.78B
Current assets17.51B17.00B18.64B20.77B18.67B
PP&E, netmay include right-of-use assets (IFRS)9.32B9.23B9.02B8.93B9.93B
Goodwill7.02B6.98B6.81B7.05B10.55B
Intangibles16.75B15.52B14.77B14.32B30.08B
Total assets61.12B59.46B59.01B60.15B79.10B
Current liabilities21.39B21.70B21.07B22.81B23.67B
Short-term debt3.01B2.35B2.81B3.95B3.60B
Long-term debt14.71B14.64B15.21B17.04B20.57B
Total debt17.72B16.99B18.02B20.99B24.17B
Total liabilities45.16B46.38B46.21B50.05B57.76B
Shareholders' equity16.38B13.67B13.35B10.60B15.05B
Net debt14.32B13.12B15.08B17.26B19.90B
Cash flow statement
Operating cash flow7.74B6.55B6.77B7.40B7.95B
Capital expenditure1.35B1.40B1.31B1.14B950.00M
Free cash flow6.39B5.16B5.45B6.26B7.00B
Investing cash flow-4.23B-1.23B-1.59B-8.77B-1.78B
Financing cash flow-3.69B-4.73B-5.64B823.00M-7.59B
Depreciation & amortization2.31B2.55B2.29B2.15B2.12B
Stock-based compensation374.00M344.00M307.00M346.00M343.00M
Dividends paid2.56B2.44B2.25B3.47B4.00B
Share buybacks1.38B00——

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.